What is Oncoustics?
Oncoustics is at the forefront of developing advanced AI and machine learning solutions tailored for point-of-care diagnostics. The company's core focus lies in the non-invasive surveillance and monitoring of liver diseases. By leveraging standard ultrasound devices, Oncoustics' suite of applications empowers clinicians to conduct rapid and cost-effective liver diagnostics. This innovation aims to democratize access to critical healthcare services, enhance the patient experience, and ultimately improve clinical outcomes through earlier detection and more efficient workflows. The company is actively engaged with international clinical partners to validate its technology and broaden its application scope within the global healthcare ecosystem.
How much funding has Oncoustics raised?
Oncoustics has raised a total of $5M across 1 funding round:
Angel/Seed
$5M
Angel/Seed (2022): $5M with participation from Creative Ventures and Saltagen Ventures
Key Investors in Oncoustics
Creative Ventures
Creative Ventures is an investment firm that has participated in Oncoustics' funding round. Further details on their specific investment focus are not provided.
Saltagen Ventures
Saltagen Ventures empowers early-stage deep biotechnology startups to grow their businesses globally, focusing on the North American and Asian markets. The company specializes in identifying and scaling high-growth potential bioscience technology firms with strong fundamental technology. By investing from seed to Series B and maintaining capital for follow-on investments, Saltagen Ventures collaborates closely with founders to drive successful exits. Their seasoned team leverages extensive investment and entrepreneurial experience to facilitate connections between the Canadian and Hong Kong technology ecosystems.
What's next for Oncoustics?
The recent major strategic investment signals a pivotal growth phase for Oncoustics, likely moving beyond its initial development stages into a scaling or expansion phase. This capital infusion is expected to accelerate product development, enhance market penetration, and potentially support further clinical validation and regulatory approvals. The company's focus on AI-driven diagnostics for liver disease positions it to capture significant market share in a growing sector, with future endeavors likely involving strategic partnerships and broader adoption of its technology in clinical settings worldwide.
See full Oncoustics company page
